Evidence map›Paper›PMID 32562355›Full record

ArticleJournal of the International AIDS Society2020

Layering and scaling up chronic non-communicable disease care on existing HIV care systems and acute care settings in Kenya: a cost and budget impact analysis.

Brianna Osetinsky, Ann Mwangi, Sonak Pastakia, Marta Wilson-Barthes, Joan Kimetto, Kimutai Rono, Jeremiah Laktabai, Omar Galárraga

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Brianna OsetinskyHealth Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA.
Ann MwangiAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Sonak PastakiaDepartment of Pharmacy Practice, Purdue Kenya Partnership, Purdue University College of Pharmacy, Eldoret, Kenya.
Marta Wilson-BarthesHealth Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA.
Joan KimettoAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Kimutai RonoAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Jeremiah LaktabaiAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Omar GalárragaHealth Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA.ORCID 0000-0002-9985-9266
AMPATH · KEBrown University · USMoi University · KEPurdue Pharma (Canada) · CASwiss Tropical and Public Health Institute · CH

Funding

Science/Technical CoreP2CHD041020 · NICHD · BROWN UNIVERSITY · PI ZHENCHAO QIAN · 2016 to 2026
$7.6M
NICHD NIH HHS P2C HD041020NIH HHS P30-AI-042853
6 · The paper itself

Abstract

introductionLike many countries in sub-Saharan Africa, Kenya is experiencing a rapid rise in the burden of non-communicable diseases (NCDs): NCDs now contribute to over 50% of inpatient admissions and 40% of hospital deaths in the country. The Academic Model Providing Access to Healthcare (AMPATH) Chronic Disease Management (CDM) programme builds on lessons and capacity of HIV care to deliver chronic NCD care layered into both HIV and primary care platforms to over 24,000 patients across 69 health facilities in western Kenya. We conducted a cost and budget impact analysis of scaling up the AMPATH CDM programme in western Kenya using the International Society for Pharmacoeconomics and Outcomes Research guidelines.

methodsCosts of the CDM programme for the health system were measured retrospectively for 69 AMPATH clinics from 2014 to 2018 using programmatic records and clinic schedules to assign per clinic monthly costs. We quantified the additional costs to provide NCD care above those associated with existing HIV or acute care services, including clinician, staff, training, travel and equipment costs, but do not include drugs or consumables as they would be paid by the patient. We projected the budget impact of increasing CDM coverage to 50% of the eligible population from 2021 to 2025, and compared it with the county budgets from 2019.

resultsThe per visit cost of providing CDM care was $10.42 (SD $2.26), with costs at facilities added to HIV clinics $1.00 (95% CI: -$2:11 to $0.11) lower than at primary care facilities. The budget impact of adding 26,765 patients from 2021 to 2025 to the CDM programme was 3,088,928 under constant percent growth, and 3,451,732 under steady-state enrolment. Scaling up under the constant percent growth scenario resulted in 12% cost savings in the budget impact. The county programmatic CDM cost in 2025 was <1% of the county healthcare budgets from 2019.

conclusionsThe budget impact of scaling up AMPATH's CDM programme will be driven by annual growth scenarios, and facility/provider mix. By leveraging task shifting, referral systems and partnering with public and non-profit clinics without NCD services, AMPATH's CDM programme can provide critical NCD care to new, rural populations with minimal financial impact.

Indexed as

Health Care CostsHealth Services AccessibilityAdultAmbulatory Care FacilitiesHIV InfectionsHumansKenyaNoncommunicable DiseasesPrimary Health CareRetrospective Studiesbudget impactchronic carecostingHIVintegratedmodellingnon-communicable disease

Identifiers

PMID32562355
PMCPMC7305417
OpenAlexW3036783534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.